Recent developments on therapeutic and diagnostic approaches for COVID-19
J Majumder, T Minko - The AAPS journal, 2021 - Springer
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health …
[HTML][HTML] SARS-CoV-2 vaccines: status report
F Amanat, F Krammer - Immunity, 2020 - cell.com
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here …
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here …
Arbidol as a broad-spectrum antiviral: an update
J Blaising, SJ Polyak, EI Pécheur - Antiviral research, 2014 - Elsevier
Arbidol (ARB) is a Russian-made small indole-derivative molecule, licensed in Russia and
China for prophylaxis and treatment of influenza and other respiratory viral infections. It also …
China for prophylaxis and treatment of influenza and other respiratory viral infections. It also …
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements
A Pandey, AN Nikam, AB Shreya, SP Mutalik… - Life sciences, 2020 - Elsevier
The present pandemic of SARS-CoV-2 has been a tough task for the whole world to deal
with. With the absence of specific drugs or vaccines against SARS-CoV-2, the situation is …
with. With the absence of specific drugs or vaccines against SARS-CoV-2, the situation is …
Mannich bases in medicinal chemistry and drug design
G Roman - European journal of medicinal chemistry, 2015 - Elsevier
The biological activity of Mannich bases, a structurally heterogeneous class of chemical
compounds that are generated from various substrates through the introduction of an …
compounds that are generated from various substrates through the introduction of an …
Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates
L Rodrigues, R Bento Cunha, T Vassilevskaia… - Molecules, 2022 - mdpi.com
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses
EI Pécheur, V Borisevich, P Halfmann… - Journal of …, 2016 - Am Soc Microbiol
Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB
is currently used clinically in several countries but not in North America. We have previously …
is currently used clinically in several countries but not in North America. We have previously …
Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis
Abstract Emerging from Wuhan, China, SARS-CoV-2 is the new global threat that killed
millions of people, and many are still suffering. This pandemic has not only affected people …
millions of people, and many are still suffering. This pandemic has not only affected people …
Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses
CE Hulseberg, L Fénéant… - Journal of …, 2019 - Am Soc Microbiol
Antiviral therapies that impede virus entry are attractive because they act on the first phase
of the infectious cycle. Drugs that target pathways common to multiple viruses are …
of the infectious cycle. Drugs that target pathways common to multiple viruses are …
Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations
The COVID-19 pandemic has spread rapidly and poses an unprecedented threat to the
global economy and human health. Broad-spectrum antivirals are currently being …
global economy and human health. Broad-spectrum antivirals are currently being …